Chart pattern: Inverse Head and Shoulders (weekly)
▲ Broken out
Broke on Oct 16, 2026 · measured target $118.42 (+16%). Details →
Oct 19, 4:23 PM ET
Medtronic said on October 15, 2026 that its exchange offer for MiniMed Group shares had settled and the separation was complete. The offer was 5.4 times subscribed, and Medtronic exchanged its remaining 252,813,348 MiniMed shares, ending its ownership stake in MiniMed. The same filing reports shareholder approval of all six AGM proposals and a leadership expansion for Michael Marinaro, with a base salary of $1,000,000 for fiscal 2027.
- Exchange offer settled October 15, 2026; Medtronic exchanged all remaining interest, 252,813,348 MiniMed shares, and the offer was 5.4 times subscribed
- Michael Marinaro appointed President, Medtronic, effective October 14, 2026, with oversight of Greater China operations; base salary set at $1,000,000 for fiscal 2027
- Supplemental fiscal 2027 long-term incentive awards with an aggregate target value of approximately $3.25 million, to be granted November 2, 2026
- All twelve director nominees were elected at the October 15, 2026 Annual General Meeting, and all six proposals passed
Read the filing on SEC.gov ↗
Sep 17, 4:19 PM ET
Medtronic filed an 8-K on September 17, 2026 to correct a typographical error in the prospectus for its exchange offer of MiniMed Group common stock for Medtronic ordinary shares. The prospectus had stated that a notice of guaranteed delivery would expire at 12:00 midnight, New York City time, while the corrected deadline is 5:00 p.m. New York City time on the second NYSE trading day after the notice is executed. Shareholders who plan to use guaranteed delivery need to meet the corrected deadline.
- Medtronic commenced the exchange offer on September 14, 2026, for up to 225,361,295 newly issued MiniMed common shares.
- The guaranteed delivery deadline is corrected to 5:00 p.m. New York City time on the second NYSE trading day after execution of the notice.
- If the offer is oversubscribed, Medtronic currently intends to accept additional shares not exceeding two percent of total outstanding Medtronic ordinary shares.
- Shareholders should read the Prospectus; D.F. King & Co., Inc. is the information agent at (877) 361-7972.
Read the filing on SEC.gov ↗
Sep 1, 6:47 AM ET
Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and GAAP diluted EPS of $1.14 versus $0.81 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75% and its non-GAAP diluted EPS guidance to $5.94 to $6.00, both measures improving on the prior outlook.
- Q1 revenue of $9.756 billion, up 13.7% as reported and organically; the extra fiscal week benefited organic growth by approximately $570 million, per the company
- Q1 GAAP diluted EPS of $1.14, up 40.7%; non-GAAP diluted EPS of $1.45, up 15.1%
- FY27 organic revenue growth guidance raised to 7.25% to 7.75% from 6.75% to 7.25%
- FY27 non-GAAP diluted EPS guidance raised to $5.94 to $6.00 from $5.90 to $6.00
Read the filing on SEC.gov ↗
Jun 3, 6:47 AM ET
Medtronic reported fiscal 2026 revenue of $36.4 billion, up 8.4% as reported and 5.8% organic, and fourth-quarter revenue of $9.8 billion, up 9.9%. Fiscal 2026 non-GAAP diluted EPS rose 0.7% to $5.53, while non-GAAP operating margin fell 130 basis points, and fourth-quarter non-GAAP diluted EPS fell 4.3% to $1.55. The company guided fiscal 2027 non-GAAP diluted EPS to $5.90 to $6.00 and raised its quarterly dividend to $0.72 per share.
- Q4 revenue was $9.807 billion, up 9.9% as reported and 6.6% organic.
- Q4 GAAP diluted EPS was $0.96, up 17.1%; non-GAAP diluted EPS was $1.55, down 4.3%.
- FY27 guidance calls for organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS of $5.90 to $6.00.
- Quarterly dividend raised to $0.72 per share, payable July 17, 2026, to holders of record on June 26, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.